4D Molecular director granted 50K stock options
4D Molecular Therapeutics director Glenn Sblendorio received a grant of stock options for 50,000 shares of Common Stock.
Rhea-AI Filing Summary
4D Molecular Therapeutics director Glenn Sblendorio received a grant of stock options for 50,000 shares of Common Stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036, and are held directly.
The grant was automatically made under the company’s non-employee director compensation program. One-third of the options vest on June 17, 2027, with the remaining shares vesting in equal monthly installments until full vesting on June 17, 2029, or earlier upon a Change in Control under the 2020 Incentive Award Plan. Following this award, Sblendorio holds options for 50,000 shares from this grant.
Insider Trade Summary
Grant/Award: 50,000 shares
Grant/Award
1 txn
Insider
SBLENDORIO GLENN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,000 contracts (Direct)
Footnotes (2)
- F1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- F2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Key Figures
Option grant size: 50,000 shares
Exercise price: $9.42 per share
Post-grant option holdings from this award: 50,000 options
+3 more
6 metrics
Option grant size
50,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$9.42 per share
Conversion or exercise price of granted options
Post-grant option holdings from this award
50,000 options
Total shares following transaction for this grant
Option expiration date
June 16, 2036
Expiration date of granted stock options
Initial vesting date
June 17, 2027
1/3 of total shares vest on this date
Full vesting date
June 17, 2029
All options fully vested by this date absent acceleration
Key Terms
Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
non-employee director compensation program financial
"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."
Change in Control financial
"will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2020 Incentive Award Plan financial
"Change in Control (as defined in the 2020 Incentive Award Plan)."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did FDMT director Glenn Sblendorio report?
Glenn Sblendorio reported receiving a grant of stock options for 50,000 shares. These options give him the right to buy 4D Molecular Therapeutics common stock at a fixed price as part of his non-employee director compensation package.
What is the exercise price of Glenn Sblendorio’s FDMT stock options?
The stock options have an exercise price of $9.42 per share. This is the fixed price at which he may purchase 4D Molecular Therapeutics common shares once the options vest, regardless of future market price movements.
How do Glenn Sblendorio’s FDMT stock options vest over time?
One-third of the options vest on June 17, 2027, with the rest vesting monthly until June 17, 2029. Vesting requires Sblendorio to continue serving the company through each vesting date to earn those option portions.
When do Glenn Sblendorio’s FDMT stock options expire?
The granted stock options expire on June 16, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to acquire 4D Molecular Therapeutics common shares at the $9.42 exercise price.
Were Glenn Sblendorio’s FDMT options part of a standard compensation program?
Yes, the options were automatically granted under the non-employee director compensation program. This indicates the grant is a routine element of director pay, rather than a discretionary, one-time award outside the company’s established plan.
Can Glenn Sblendorio’s FDMT options vest earlier than scheduled?
Yes, the options will fully vest upon a Change in Control as defined in the 2020 Incentive Award Plan. In that event, all unvested options become exercisable, accelerating his ability to purchase common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
